Skip to content
Quebec News Tribune – Lifestyle
Author:
Neutrolis, Inc.
Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency
July 15, 2026
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
April 15, 2026
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
April 2, 2026